Capital Advisors Ltd’s 10x Genomics TXG Stock Holding History

Capital Advisors Ltd’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5K	Hold	136	–	–	﹤0.01%	982
2026 Q1	$3K	Hold	136	–	–	﹤0.01%	1061
2025 Q4	$2K	Hold	136	–	–	﹤0.01%	1108
2025 Q3	$2K	Hold	136	–	–	﹤0.01%	1100
2025 Q2	$2K	Sell	136 -702	-84%	-$6.4K	﹤0.01%	1106
2025 Q1	$7K	Buy	+838	New	+$10.6K	﹤0.01%	866
2024 Q3	–	Sell	-513	Closed	-$10K	–	1613
2024 Q2	$10K	Buy	513 +404	+371%	+$10.6K	﹤0.01%	757
2024 Q1	$4K	Sell	109 -22	-17%	-$967	﹤0.01%	941
2023 Q4	$7K	Hold	131	–	–	﹤0.01%	768
2023 Q3	$5K	Sell	131 -8	-6%	-$416	﹤0.01%	841
2023 Q2	$8K	Hold	139	–	–	﹤0.01%	742
2023 Q1	$8K	Buy	139 +7	+5%	+$327	﹤0.01%	602
2022 Q4	$5K	Buy	132 +107	+428%	+$3.5K	﹤0.01%	677
2022 Q3	$1K	Buy	+25	New	+$952	﹤0.01%	1136

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Advisors Ltd's TXG Position: Q2 2026 in Review

Capital Advisors Ltd held its 10x Genomics (TXG) position steady in Q2 2026 at 136 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Capital Advisors Ltd first reported a position in TXG in Q3 2022 and has held it in 14 quarters since. The position peaked at $10K in Q2 2024. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Capital Advisors Ltd held 136 shares of 10x Genomics worth $5K as of Q2 2026.
Capital Advisors Ltd left its 10x Genomics share count unchanged in Q2 2026.
10x Genomics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #982 holding.
Capital Advisors Ltd first reported a position in 10x Genomics in Q3 2022 and has held it in 14 quarters since.
Capital Advisors Ltd's 10x Genomics position peaked at $10K in Q2 2024.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.